Vol. 5 (2021): International Journal of Case Reports
Case Reports

A Rare Occurrence of Primary Breast Mucormycosis, A Case Report

Dr. Sanjeev Shah, Dr. Kamlesh Patel, Dr. Chetna Bhullar, Dr. Nidhi Barot
Sterling Accuris diagnostic laboratory, Ahmedabad.


  • Zygomycosis, immunosuppressed, histopathology, culture, antifungal agents

How to Cite

Dr. Sanjeev Shah, Dr. Kamlesh Patel, Dr. Chetna Bhullar, Dr. Nidhi Barot. (2021). A Rare Occurrence of Primary Breast Mucormycosis, A Case Report. International Journal of Case Reports, 5, 222. https://doi.org/10.28933/ijcr-2021-06-0205


Zygomycosis occurs primarily in immunosuppressed patients and those with diabetes mellitus. Incidence of zygomycosis has increased among transplant recipients, patients with hematologic malignancy and Covid-19 associated pulmonary complications. Soft tissue zygomycosis may be localized, extend to deep underlying tissues, or may be disseminated. The most common clinical presentation is induration of the skin with surrounding erythema, rapidly progressing to necrosis.Histological examination and culture of soft tissue are important for the diagnosis of cutaneous zygomycosis. Treatment consists of surgical excision or debridement, reversal of predisposing factors and administration of antifungal agents (amphotericin B formulations, Posaconazole/or Isavuconazole).


  1. Ribes JA, Vanover-Sams CL, Baker DJ et al. Zygomycetes in human disease. Clinical Microbiology Reviews 2000; e.g. 236–301.
  2. Kauffman CA, Malani AN et al. Zygomycosis: an emerging fungal infection with new options for management. Current Infectious Disease Reports 2007; e.g.435- 40.
  3. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Current Opinion in Infectious Disease. 2004; e.g.517-21.
  4. Spellberg B, Edwards J Jr, Ibrahim A et al. Novel perspectives on mucormycosis:pathophysiology, presentation and management. Clinical Microbiology Reviews 2005; e.g. 556–569.
  5. Parfrey NA et al. Improved diagnosis and prognosis of mucormycosis:Aclinicopathologic study of 33 cases. Medicine (Baltimore) 1986; e.g.113-23.
  6. Diamond, R. D., C. C. Haudenschild, and N. F. Erickson et al. Monocyte-mediated damage to Rhizopusoryzae hyphae in vitro. Infection & Immunity.1982 e.g. 292-297.
  7. Nithyanandam, S., M. S. Jacob, R. R. Battu, R. K. Thomas, M. A. Correa, and O. D’Souza et al. Rhino-orbito-cerebral mucorycosis. A retrospective analysis of clinical features and treatment outcomes. Indian Journal of Ophthalmology. 2003, e.g.231-236.
  8. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ. Kontoyiannis DP et al. epidemiology and clinical manifestations of mucormycosis. Clinical Infectious Diseases. 2012; e.g. 23–34.
  9. Pagano L, Valentini CG, Posteraro B et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (FederazioneItaliana di MicopatologiaUmanaedAnimale and European Confederation of Medical Mycology). Journal of Chemotherapy 2009; e.g.322–9.
  10. Thapar VK, Deshpande A, Jain VK, Bhowate P, Madiwale C et al. Isolated breast mucormycosis. Journal of Postgraduate Medicine 2006, e.g. 134-5.
  11. SR Baezzat1*, A Fazelzadeh1, S Tahmasebi1, PV Kumar2 et al. Primary Breast Mucormycosis, A Case Report. Iranian Red Crescent Medical Journal 2011; e.g. 208-209